CLVS Clovis Oncology, Inc. Stock Quote

CLVS [NASD]

Index	-	P/E	-	EPS (ttm)	-2.83	Insider Own	0.40%	Shs Outstand	121.22M	Perf Week	-13.75%
Market Cap	404.20M	Forward P/E	-	EPS next Y	-1.44	Insider Trans	-6.93%	Shs Float	116.49M	Perf Month	-41.15%
Income	-299.10M	PEG	-	EPS next Q	-0.40	Inst Own	48.50%	Short Float	22.72%	Perf Quarter	-40.26%
Sales	156.10M	P/S	2.59	EPS this Y	41.10%	Inst Trans	9.77%	Short Ratio	8.34	Perf Half Y	-49.36%
Book/sh	-1.86	P/B	-	EPS next Y	39.60%	ROA	-53.50%	Target Price	5.94	Perf Year	-48.98%
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	147.30%	52W Range	2.93 - 11.10	Perf YTD	-42.50%
Dividend	-	P/FCF	-	EPS past 5Y	14.90%	ROI	-75.30%	52W High	-75.14%	Beta	1.66
Dividend %	-	Quick Ratio	1.90	Sales past 5Y	-	Gross Margin	74.40%	52W Low	-5.80%	ATR	0.24
Employees	429	Current Ratio	2.00	Sales Q/Q	-2.30%	Oper. Margin	-	RSI (14)	27.06	Volatility	8.65% 6.45%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	37.60%	Profit Margin	-	Rel Volume	1.68	Prev Close	3.11
Shortable	Yes	LT Debt/Eq	-	Earnings	Nov 03 BMO	Payout	-	Avg Volume	3.17M	Price	2.76
Recom	3.30	SMA20	-24.48%	SMA50	-33.04%	SMA200	-46.70%	Volume	5,320,777	Change	-11.25%

May-18-20

Reiterated

H.C. Wainwright

Buy

$29 → $33

Apr-27-20

Downgrade

SVB Leerink

Mkt Perform → Underperform

Apr-09-20

Downgrade

BofA/Merrill

Neutral → Underperform

Jan-08-20

Reiterated

H.C. Wainwright

Buy

$36 → $27

Nov-19-19

Downgrade

Evercore ISI

Outperform → In-line

Sep-24-19

Downgrade

SVB Leerink

Outperform → Mkt Perform

$22 → $10

Aug-13-19

Downgrade

BofA/Merrill

Buy → Neutral

Aug-02-19

Downgrade

Guggenheim

Buy → Neutral

May-29-19

Downgrade

Goldman

Neutral → Sell

Apr-15-19

Reiterated

H.C. Wainwright

Buy

$39 → $37

Feb-13-19

Initiated

H.C. Wainwright

Buy

$40

Dec-04-18

Upgrade

Leerink Partners

Mkt Perform → Outperform

Oct-31-18

Downgrade

JP Morgan

Overweight → Neutral

Oct-19-18

Resumed

Piper Jaffray

Neutral

Sep-25-18

Initiated

Leerink Partners

Mkt Perform

Feb-22-18

Upgrade

RBC Capital Mkts

Sector Perform → Outperform

Feb-22-18

Upgrade

Evercore ISI

In-line → Outperform

Oct-23-17

Initiated

Barclays

Overweight

$105

Sep-15-17

Initiated

RBC Capital Mkts

Sector Perform

$81

Aug-17-17

Initiated

Evercore ISI

In-line

$73

Dec-03-21 11:31AM	Why Is Clovis (CLVS) Down 32% Since Last Earnings Report? Zacks -11.25%
Nov-04-21 06:46AM	Clovis (CLVS) Q3 Loss Wider Than Expected, Revenues Lag Zacks
Nov-03-21 09:15AM	Clovis Oncology (CLVS) Reports Q3 Loss, Lags Revenue Estimates Zacks
08:00AM	Clovis Oncology Announces Third Quarter 2021 Operating Results Business Wire
07:48AM	Shareholders in Clovis Oncology (NASDAQ:CLVS) are in the red if they invested five years ago Simply Wall St.
Oct-27-21 03:03PM	Clovis Oncology (CLVS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks -5.29%
Oct-20-21 08:00AM	Clovis Oncology to Announce Third Quarter 2021 Financial Results and Host Webcast Conference Call on November 3 Business Wire
Oct-19-21 08:00AM	Clovis Oncology and ITM Announce Lutetium-177 Clinical Supply Agreement Business Wire
Oct-15-21 09:15AM	Clovis (CLVS) Focuses on Rubraca Growth Amid Rising Competition Zacks
Oct-07-21 09:00AM	Pan-Cancer Analysis Suggests Fibroblast Activation Protein (FAP) is an Attractive Target for Peptide-Targeted Radionuclide Therapy with FAP-2286 Business Wire
Sep-29-21 10:00AM	Can These Former Biotech Growth Stocks Regain Their Form? Motley Fool
Sep-20-21 08:00AM	Clovis Oncology Retires Remaining 2021 Notes and Raises Additional Capital through its ATM Equity Offering Program Business Wire -5.58%
Sep-03-21 11:31AM	Clovis (CLVS) Down 3.2% Since Last Earnings Report: Can It Rebound? Zacks -5.71%
Aug-27-21 11:37AM	Why Clovis Oncology Shares Got a Bump This Week Motley Fool
Aug-24-21 02:00AM	Clovis Oncology Announces Availability of and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Switzerland Business Wire
Aug-16-21 04:21PM	Clovis Oncology Announces Renewal of At-The-Market Equity Offering Program Business Wire
Aug-05-21 10:57AM	Clovis (CLVS) Q2 Earnings Miss, PARP Drug Rubraca Sales Down Zacks
02:34AM	What Kind Of Investors Own Most Of Clovis Oncology, Inc. (NASDAQ:CLVS)? Simply Wall St.
Aug-04-21 09:15AM	Clovis Oncology (CLVS) Reports Q2 Loss, Lags Revenue Estimates Zacks
08:00AM	Clovis Oncology Announces Second Quarter 2021 Operating Results Business Wire
Jul-28-21 03:03PM	Will Clovis Oncology (CLVS) Report Negative Earnings Next Week? What You Should Know Zacks
Jul-21-21 08:00AM	Clovis Oncology to Announce Second Quarter 2021 Financial Results and Host Webcast Conference Call on August 4 Business Wire
Jul-12-21 04:05PM	Clovis Oncology Appoints Dr. Ronit Simantov to its Board of Directors Business Wire
Jun-28-21 07:00AM	Initial Clinical Experience of FAP-2286 in Independent Named Patient Use Published in The Journal of Nuclear Medicine Business Wire -5.66%
Jun-23-21 07:00AM	Clovis Oncology Announces LuMIERE Clinical Trial Evaluating Novel Peptide-Targeted Radionuclide Therapy FAP-2286 Now Open for Enrollment Business Wire
Jun-15-21 05:39AM	2 Great Reasons to Buy This Cancer Treatment Stock Now Motley Fool
Jun-12-21 06:49AM	Here's Why Wall Street Is Betting Against Clovis Oncology Motley Fool
Jun-10-21 04:30PM	Clovis Oncology Announces Partial Adjournment of Annual Meeting of Stockholders Business Wire -5.39%
Jun-09-21 11:00AM	Why Clovis Oncology Stock Is Rocketing Higher Today Motley Fool +10.51%
06:36AM	Geo, ContextLogic, Clovis Oncology Get Swept Up in Meme Stock Surge TheStreet.com
Jun-04-21 11:31AM	Clovis (CLVS) Down 5.3% Since Last Earnings Report: Can It Rebound? Zacks
May-19-21 06:27PM	Clovis Oncology Highlights Rubraca® (rucaparib) and Lucitanib Data at 2021 ASCO Annual Meeting Business Wire
May-17-21 04:15PM	Clovis Oncology Announces At-The-Market Equity Offering Program Business Wire
May-07-21 03:09AM	If You Had Bought Clovis Oncology's (NASDAQ:CLVS) Shares Three Years Ago You Would Be Down 88% Simply Wall St.
May-06-21 10:39AM	Clovis (CLVS) Q1 Earnings Beat, COVID-19 Hurts Rubraca Sales Zacks
May-05-21 10:04AM	Clovis Oncology Reports 11% Drop In Q1 Sales As COVID-19 Hit Rubraca Sales Benzinga +6.35%
09:15AM	Clovis Oncology (CLVS) Reports Q1 Loss, Misses Revenue Estimates Zacks
08:00AM	Clovis Oncology Announces First Quarter 2021 Operating Results Business Wire
06:45AM	Clovis Oncology, Inc. to Host Earnings Call ACCESSWIRE
Apr-28-21 04:05PM	Clovis Oncology to Present at the Bank of America 2021 Health Care Conference Business Wire
12:33PM	Will Clovis Oncology (CLVS) Report Negative Earnings Next Week? What You Should Know Zacks
Apr-21-21 04:00PM	Clovis Oncology to Announce First Quarter 2021 Financial Results and Host Webcast Conference Call on May 5 Business Wire +5.82%
Apr-10-21 08:30AM	Clovis Oncology Highlights Rubraca® (rucaparib) Clinical Data at AACR Virtual Annual Meeting 2021 Business Wire
Mar-25-21 11:30AM	Why Is Clovis (CLVS) Up 4.4% Since Last Earnings Report? Zacks
Mar-22-21 09:50AM	Return On Capital Employed Overview: Clovis Oncology Benzinga
08:34AM	Are Options Traders Betting on a Big Move in Clovis Oncology (CLVS) Stock? Zacks
07:17AM	Clovis (CLVS) Stock Jumps 47.7%: Will It Continue to Soar? Zacks
Mar-19-21 04:30PM	Why Clovis Oncology Stock Skyrocketed Today Motley Fool +47.74%
11:13AM	Return On Capital Employed Overview: Clovis Oncology Benzinga
09:24AM	5 Top Stock Gainers for Friday: FedEx, Dollar General, Clovis TheStreet.com
08:19AM	Clovis Oncology stock soars after ovarian cancer treatment meets primary endpoint MarketWatch
08:00AM	Clovis Oncologys Rubraca® (rucaparib) Significantly Improves Progression-Free Survival versus Chemotherapy in Patients with Later-line Ovarian Cancer Associated with a BRCA Mutation Business Wire
06:50AM	Clovis Oncology Skyrockets on Ovarian Cancer Drug Success TheStreet.com
Mar-02-21 10:21AM	Understanding Clovis Oncology's Unusual Options Activity Benzinga -8.19%
Feb-23-21 09:24AM	Clovis Oncology: Q4 Earnings Insights Benzinga -10.03%
08:00AM	Clovis Oncology Announces 2020 Operating Results Business Wire
06:30AM	Clovis Oncology, Inc. to Host Earnings Call ACCESSWIRE
Feb-22-21 10:14AM	Earnings Preview for Clovis Oncology Benzinga
Feb-17-21 08:00AM	Clovis Oncology to Announce Fourth Quarter and Year-End 2020 Financial Results and Host Webcast Conference Call on February 23 Business Wire
Feb-11-21 08:00AM	Clovis Oncology Presents Data in Advanced Prostate Cancer at ASCO 2021 Genitourinary Cancers Symposium Virtual Meeting Business Wire -9.91%
Feb-06-21 02:41AM	Could The Clovis Oncology, Inc. (NASDAQ:CLVS) Ownership Structure Tell Us Something Useful? Simply Wall St.
Feb-04-21 08:00AM	Clovis Oncology to Highlight Data at ASCO 2021 Genitourinary Cancers Symposium Virtual Meeting Business Wire
Feb-02-21 10:00AM	Alexion (ALXN) to Report Q4 Earnings: What's in the Cards? Zacks
Jan-11-21 08:00AM	Clovis Oncology Announces Preliminary Product Revenues for the Fourth Quarter and Full Year 2020 Business Wire +11.29%
Dec-30-20 06:49AM	Clovis (CLVS) Seeks Permission for Clinical Study on Novel Drug Zacks +10.56%
Dec-29-20 08:00AM	Clovis Oncology Submits Investigational New Drug Applications for Novel Peptide-Targeted Radionuclide FAP-2286 for Therapeutic and Imaging Clinical Trial Business Wire
Dec-22-20 10:28AM	Company News for Dec 22, 2020 Zacks
10:05AM	Clovis' (CLVS) Rubraca Confirmatory Study Meets Endpoint Zacks
Dec-21-20 10:05AM	Looking Into Clovis Oncology's Return On Capital Employed Benzinga +7.04%
08:00AM	Clovis Oncologys Rubraca® (rucaparib) Met the Primary Endpoint of Significantly Improving Progression-Free Survival vs. Chemotherapy in the ARIEL4 Randomized Phase 3 Treatment Study in Later-line Ovarian Cancer Patients with a BRCA mutation Business Wire
Dec-16-20 10:51PM	Is CLVS A Good Stock To Buy Now? Insider Monkey
Dec-10-20 08:55AM	Is the Options Market Predicting a Spike in Clovis Oncology (CLVS) Stock? Zacks
Dec-05-20 11:32AM	Clovis (CLVS) Up 18.6% Since Last Earnings Report: Can It Continue? Zacks
Nov-24-20 06:06PM	Clovis Oncology Announces Exercise by Existing Holder of Option to Purchase an Additional $7.5 Million Aggregate Principal Amount of the Companys 4.50% Convertible Senior Notes Due 2024 Business Wire +5.02%
Nov-20-20 08:00AM	Clovis Oncology to Present at the Piper Sandler 32nd Annual Healthcare Conference Business Wire
Nov-08-20 07:40AM	Clovis Oncology, Inc. (NASDAQ:CLVS) Analysts Are Cutting Their Estimates: Here's What You Need To Know Simply Wall St.
Nov-06-20 10:43AM	Clovis (CLVS) Q3 Earnings Top, Sales Show Coronavirus Impact Zacks
Nov-05-20 09:25AM	Clovis Oncology (CLVS) Reports Q3 Loss, Lags Revenue Estimates Zacks -21.16%
08:05AM	Clovis Oncology Announces Third Quarter 2020 Operating Results Business Wire
08:02AM	Clovis Oncology Announces Debt Exchange Transaction and Offering of Convertible Senior Notes Business Wire
Oct-29-20 12:35PM	Will Clovis Oncology (CLVS) Report Negative Earnings Next Week? What You Should Know Zacks
Oct-20-20 04:05PM	Clovis Oncology to Announce Third Quarter 2020 Financial Results and Host Webcast Conference Call on November 5 Business Wire
Oct-14-20 10:15PM	Hedge Funds Are Dipping Their Toes Back Into Clovis Oncology Inc (CLVS) Insider Monkey -6.24%
Oct-13-20 06:47AM	How Much Is Clovis Oncology, Inc. (NASDAQ:CLVS) Paying Its CEO? Simply Wall St. +15.70%
Sep-17-20 03:05AM	New Data Presented at ESMO Virtual Congress 2020 Highlight Breadth and Potential of Clovis Oncology Products and Pipeline Business Wire
Sep-10-20 08:05AM	Clovis Oncology Announces Oral Plenary Session Presentation at International Gynecologic Cancer Society (IGCS) Digital Annual Global Meeting Business Wire +5.63%
Sep-09-20 08:05AM	Clovis Oncology to Highlight Data for its Three Portfolio Compounds at the ESMO Virtual Congress 2020 Business Wire
Sep-08-20 04:19PM	Clovis Oncology to Present at the H.C. Wainwright 22nd Annual Global Investment Conference Business Wire
08:53AM	Are Options Traders Betting on a Big Move in Clovis Oncology (CLVS) Stock? Zacks
Sep-05-20 11:31AM	Clovis (CLVS) Down 17.3% Since Last Earnings Report: Can It Rebound? Zacks
Aug-27-20 09:58AM	ROCE Insights For Clovis Oncology Benzinga
08:02AM	The Daily Biotech Pulse: Liver Congress Underway, FDA Approves Companion Diagnostic Test For Clovis Cancer Drug, EUA For Abbott's $5, 15-Minute COVID-19 Test Benzinga
Aug-26-20 07:23PM	FDA Approves FoundationOne® Liquid CDx to Serve as Rubraca® (rucaparib) Companion Diagnostic to Identify Eligible Patients with BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (mCRPC) Business Wire
Aug-18-20 10:36AM	Return On Capital Employed Overview: Clovis Oncology Benzinga
Aug-17-20 03:13PM	Why Clovis Oncology's Stock Is Trading Higher Today Benzinga +20.12%
08:05AM	Journal of Clinical Oncology Publishes Additional Data from Clovis Oncologys TRITON2 Clinical Trial Evaluating Rubraca® (rucaparib) for the Treatment of mCRPC in Patients with BRCA1/2 Gene Mutations Business Wire
Aug-07-20 11:44AM	Clovis (CLVS) Q2 Earnings Lag, Revenues Show Coronavirus Impact Zacks -13.00%
Aug-06-20 07:10PM	Clovis Oncology (CLVS) Reports Q2 Loss, Misses Revenue Estimates Zacks
04:05PM	Clovis Oncology Announces Second Quarter 2020 Operating Results Business Wire
Aug-05-20 08:05AM	Clovis Oncology Announces First Patient Enrolled in the Phase 2 Portion of the LIO-1 Trial Evaluating the Combination of Lucitanib and Opdivo in Gynecologic Cancers Business Wire

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally. The company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. It also provides lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3); and FAP-2286, a peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein. The company distributes its products primarily through specialty pharmacies and distributors to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH, and Bristol Myers Squibb Company; and a partnership with Foundation Medicine, Inc. The company was incorporated in 2009 and is headquartered in Boulder, Colorado.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
IVERS-READ GILLIAN C	See Remarks	Dec 02	Sale	3.00	304	912	260,041	Dec 03 04:15 PM
Harding Thomas C.	See Remarks	Dec 02	Sale	3.00	7	21	1,542	Dec 03 04:15 PM
Harding Thomas C.	See Remarks	Dec 02	Sale	3.00	141	423	5,395	Dec 03 04:15 PM
MUEHL DANIEL W	See Remarks	Dec 02	Sale	3.00	248	744	67,403	Dec 03 04:16 PM
Rolfe Lindsey	See Remarks	Dec 02	Sale	3.00	346	1,038	82,628	Dec 03 04:16 PM
Gross Paul Edward	See Remarks	Dec 02	Sale	3.00	248	744	61,357	Dec 03 04:15 PM
Rolfe Lindsey	See Remarks	Nov 02	Sale	4.55	4,209	19,151	79,987	Nov 03 04:18 PM
IVERS-READ GILLIAN C	See Remarks	Nov 02	Sale	4.55	3,696	16,817	257,074	Nov 03 04:19 PM
Harding Thomas C.	See Remarks	Nov 02	Sale	4.55	62	282	1,531	Nov 03 04:15 PM
Harding Thomas C.	See Remarks	Nov 02	Sale	4.55	1,682	7,653	4,346	Nov 03 04:15 PM
MUEHL DANIEL W	See Remarks	Nov 02	Sale	4.55	4,523	20,580	64,505	Nov 03 04:15 PM
Gross Paul Edward	See Remarks	Nov 02	Sale	4.55	4,523	20,580	58,459	Nov 03 04:15 PM
Harding Thomas C.	See Remarks	Oct 04	Sale	4.41	6	26	1,412	Oct 05 04:31 PM
IVERS-READ GILLIAN C	See Remarks	Sep 02	Sale	4.89	304	1,487	254,980	Sep 03 04:15 PM
Rolfe Lindsey	See Remarks	Sep 02	Sale	4.89	347	1,697	78,122	Sep 03 04:15 PM
Gross Paul Edward	See Remarks	Sep 02	Sale	4.89	249	1,218	55,318	Sep 03 04:15 PM
MUEHL DANIEL W	See Remarks	Sep 02	Sale	4.89	249	1,218	61,364	Sep 03 04:16 PM
Harding Thomas C.	See Remarks	Sep 02	Sale	4.89	7	34	1,403	Sep 03 05:21 PM
Harding Thomas C.	See Remarks	Sep 02	Sale	4.89	141	689	3,563	Sep 03 05:21 PM
IVERS-READ GILLIAN C	See Remarks	Aug 03	Sale	4.82	3,683	17,752	252,005	Aug 03 09:40 PM
Harding Thomas C.	See Remarks	Aug 03	Sale	4.82	62	299	1,391	Aug 03 09:38 PM
Harding Thomas C.	See Remarks	Aug 03	Sale	4.82	1,678	8,088	2,511	Aug 03 09:38 PM
MUEHL DANIEL W	See Remarks	Aug 03	Sale	4.82	4,507	21,724	58,459	Aug 03 09:36 PM
Rolfe Lindsey	See Remarks	Aug 03	Sale	4.82	4,195	20,220	75,473	Aug 03 09:32 PM
Gross Paul Edward	See Remarks	Aug 03	Sale	4.82	4,507	21,724	52,413	Aug 03 09:31 PM
Harding Thomas C.	See Remarks	Jul 01	Sale	5.79	26	151	1,272	Jul 06 04:16 PM
Gross Paul Edward	See Remarks	Jun 03	Sale	5.63	231	1,301	49,262	Jun 03 07:03 PM
MUEHL DANIEL W	See Remarks	Jun 03	Sale	5.63	231	1,301	55,308	Jun 03 07:01 PM
Rolfe Lindsey	See Remarks	Jun 03	Sale	5.63	322	1,813	73,602	Jun 03 07:00 PM
IVERS-READ GILLIAN C	See Remarks	Jun 03	Sale	5.63	283	1,593	249,905	Jun 03 06:58 PM
Harding Thomas C.	See Remarks	Jun 03	Sale	5.63	7	39	1,235	Jun 03 06:57 PM
Harding Thomas C.	See Remarks	Jun 03	Sale	5.63	131	738	1,725	Jun 03 06:57 PM
IVERS-READ GILLIAN C	See Remarks	May 04	Sale	5.54	3,952	21,894	247,059	May 04 09:43 PM
MUEHL DANIEL W	See Remarks	May 04	Sale	5.54	4,837	26,797	52,008	May 04 09:40 PM
Rolfe Lindsey	See Remarks	May 04	Sale	5.54	4,501	24,936	71,098	May 04 09:39 PM
Harding Thomas C.	See Remarks	May 04	Sale	5.54	80	443	1,224	May 04 09:40 PM
Harding Thomas C.	See Remarks	May 04	Sale	5.54	1,799	9,966	729	May 04 09:40 PM
Gross Paul Edward	See Remarks	May 04	Sale	5.54	4,838	26,803	44,870	May 04 09:39 PM
Harding Thomas C.	See Remarks	Mar 12	Sale	6.00	1,987	11,922	1,123	Mar 15 04:15 PM
Harding Thomas C.	See Remarks	Mar 12	Sale	5.99	7,367	44,128	0	Mar 15 04:15 PM
IVERS-READ GILLIAN C	See Remarks	Mar 02	Sale	6.29	580	3,648	244,695	Mar 03 06:42 PM
Harding Thomas C.	See Remarks	Mar 02	Sale	6.29	8	50	3,110	Mar 03 06:41 PM
Harding Thomas C.	See Remarks	Mar 02	Sale	6.29	299	1,881	7,241	Mar 03 06:41 PM
Gross Paul Edward	See Remarks	Mar 02	Sale	6.29	456	2,868	43,207	Mar 03 06:40 PM
Rolfe Lindsey	See Remarks	Mar 02	Sale	6.29	661	4,158	69,022	Mar 03 06:35 PM
MUEHL DANIEL W	See Remarks	Mar 01	Sale	6.29	456	2,868	47,252	Mar 03 06:46 PM
IVERS-READ GILLIAN C	See Remarks	Feb 02	Sale	7.97	10,990	87,590	234,877	Feb 03 04:15 PM
Rolfe Lindsey	See Remarks	Feb 02	Sale	7.97	11,813	94,150	60,034	Feb 03 04:15 PM
MUEHL DANIEL W	See Remarks	Feb 02	Sale	7.97	11,872	94,620	36,374	Feb 03 04:15 PM
Harding Thomas C.	See Remarks	Feb 02	Sale	7.97	5,248	41,827	4,193	Feb 03 04:15 PM
Gross Paul Edward	See Remarks	Feb 02	Sale	7.97	11,873	94,628	32,063	Feb 03 04:15 PM
Harding Thomas C.	See Remarks	Feb 02	Sale	8.17	852	6,961	2,687	Feb 19 04:17 PM
Rolfe Lindsey	See Remarks	Dec 21	Sale	5.68	1,728	9,815	58,275	Dec 23 04:52 PM
IVERS-READ GILLIAN C	See Remarks	Dec 21	Sale	5.68	829	4,709	233,086	Dec 23 04:51 PM
Rolfe Lindsey	See Remarks	Dec 15	Option Exercise	3.28	17,241	56,550	70,718	Dec 16 04:15 PM
IVERS-READ GILLIAN C	See Remarks	Dec 10	Option Exercise	3.28	68,965	226,205	284,487	Dec 14 04:20 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience